Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model

Prostate

Volumn 66, Issue 8, 2006, Pages 831-838

  Dzojic, Helena ^a   Loskog, Angelica ^a   Tötterman, Thomas H ^a   Essand, Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Adenoviral vector; CD40 ligand; Prostate cancer; TRAMP C2

Indexed keywords

ADENOVIRUS VECTOR; CASPASE; CD40 LIGAND; ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE TRANSFER; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TRANSGENIC MOUSE; TUMOR IMMUNITY; UPREGULATION; VACCINATION;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; APOPTOSIS; CANCER VACCINES; CASPASES; CD40 LIGAND; CELL LINE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENOTYPE; PROSTATIC NEOPLASMS; TRANSDUCTION, GENETIC;

EID: 33646739571     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20344     Document Type: Article

References (24)

1. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-839.
2. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-562.
3. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21(2):137-148.
4. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67(1):2-17.
5. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004;22:307-328.
6. Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfaty I, Armitage RJ, Fanslow WC, Spriggs MK, Murphy WJ. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994;83(10):2787-2794.
7. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW. CD40 and epithelial cells: Across the great divide. Immunol Today 1998;19(11):502-506.
8. Kikuchi T, Crystal RG. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther 1999;10(8):1375-1387.
9. Loskog A, Dzojic H, Vikman S, Ninalga C, Essand M, Korsgren O, Totterman TH. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment. J Immunol 2004;172(11):7200-7205.
10. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92(8):3439-3443.
11. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57(16):3325-3330.
12. Loskog A, Bjorkland A, Brown MP, Korsgren O, Malmstrom PU, Totterman TH. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol 2001;166(3):1093-1097.
13. Kikuchi T, Miyazawa N, Moore MA, Crystal RG. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res 2000;60(22):6391-6395.
14. Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med 1999;190(1):125-133.
15. Gallagher NJ, Eliopoulos AG, Agathangelo A, Oates J, Crocker J, Young LS. CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Mol Pathol 2002;55(2):110-120.
16. Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH, Young LS. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000;20(15):5503-5515.
17. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000;191(3):411-416.
18. Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z, Fein S, Schoenberger S, Levitsky HI. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999;5(7):780-787.
19. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003;10(1):1-13.
20. Kimura T, Ohashi T, Kikuchi T, Kiyota H, Eto Y, Ohishi Y. Antirumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector. Cancer Gene Ther 2003;10(11):833-839.
21. Tsuji H, Kawaguchi S, Wada T, Nagoya S, Inobe M, Yamashita T, Ishii S, Uede T. Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary rumor and pulmonary metastasis of rat osteosarcoma. Cancer Gene Ther 2002;9(9):747-755.
22. Miller G, Lahrs S, Pillarisetty VG, Shah AB, DeMatteo RP. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated rumor protection. Cancer Res 2002;62(18):5260-5266.
23. Ciavarra RP, Brown RR, Holterman DA, Garrett M, Glass WF 2nd, Wright GL Jr., Schellhammer PF, Somers KD. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Cancer Immunol Immunother 2003;52(9):535-545.
24. Grossmann ME, Brown MP, Brenner MK. Antirumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther 1997;8(16):1935-1943.